WINTON GROUP Ltd Invests $1.02 Million in Revolution Medicines, Inc. $RVMD

WINTON GROUP Ltd bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 12,783 shares of the company’s stock, valued at approximately $1,018,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Indiana Trust & Investment Management Co purchased a new stake in shares of Revolution Medicines in the 4th quarter worth about $32,000. Global Retirement Partners LLC lifted its position in shares of Revolution Medicines by 1,002.8% in the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after purchasing an additional 361 shares during the period. Torren Management LLC purchased a new stake in shares of Revolution Medicines in the 4th quarter worth about $33,000. Darwin Wealth Management LLC bought a new position in shares of Revolution Medicines in the 4th quarter worth about $40,000. Finally, Allworth Financial LP increased its stake in shares of Revolution Medicines by 57.2% in the 4th quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after acquiring an additional 210 shares in the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 4,583 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the sale, the chief operating officer directly owned 157,570 shares in the company, valued at approximately $15,675,063.60. This trade represents a 2.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Xiaolin Wang sold 2,010 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the sale, the insider owned 116,063 shares of the company’s stock, valued at approximately $11,545,947.24. This represents a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 148,592 shares of company stock worth $20,855,132 in the last 90 days. Insiders own 7.60% of the company’s stock.

Revolution Medicines Stock Up 0.7%

Shares of Revolution Medicines stock opened at $149.55 on Wednesday. The firm has a market cap of $31.79 billion, a price-to-earnings ratio of -21.15 and a beta of 1.40. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. Revolution Medicines, Inc. has a 1 year low of $34.00 and a 1 year high of $166.50. The company has a 50-day moving average of $137.59 and a 200 day moving average of $109.04.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same quarter last year, the company posted ($1.13) EPS. As a group, sell-side analysts anticipate that Revolution Medicines, Inc. will post -7.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Revolution Medicines in a research note on Monday, March 16th. They issued a “buy” rating for the company. Sanford C. Bernstein assumed coverage on shares of Revolution Medicines in a research note on Thursday, May 21st. They issued a “market perform” rating and a $151.00 price target for the company. Truist Financial assumed coverage on shares of Revolution Medicines in a research note on Monday, May 18th. They issued a “buy” rating and a $179.00 price target for the company. UBS Group assumed coverage on shares of Revolution Medicines in a research note on Friday, February 27th. They issued a “buy” rating for the company. Finally, Oppenheimer increased their price target on shares of Revolution Medicines from $165.00 to $195.00 and gave the stock an “outperform” rating in a research note on Monday, June 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Revolution Medicines presently has a consensus rating of “Buy” and a consensus target price of $123.72.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.